Arranta Bio Announces First End-to-End Manufacturing for mRNA Vaccines in its Commercial-ready GMP Facility
Arranta Bio (“Arranta”), a leading contract development and manufacturing organization (CDMO) supporting advanced therapy pioneers, today announced plans to establish contract manufacturing capacity for messenger RNA (mRNA) vaccines.